-
-
-
-
-
-
-
Takeda and Protagonist submit drug application for polycythemia vera treatment
-
-
-
-
-
-
-
Protagonist Therapeutics (PTGX) and Takeda (TAK) Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
-
-
-
-
-
-
-
Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors
-
-
-
-
-
-
-
Pre-Open Stock Movers 12/16: (SIOX) (TLRY) (PTGX) Higher; (VTVT) (PEN) (SHSP) Lower (more...)
-
-
-
1,170,824 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

